Pediatrix Medical Group (FRA:PDC) Beneish M-Score: -2.75 (As of Jun. 24, 2026)


FRA:PDC Pediatrix Medical Group Inc FRA:PDC
63 GF Score
Price €20.40
GF Value €11.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Pediatrix Medical Group Beneish M-Score?

Pediatrix Medical Group FRA:PDC -0.97% 63 Beneish M-Score is -2.75 as of Jun. 24, 2026. GuruFocus rates FRA:PDC with a GF Score™ of 63/100 and a GF Value™ of €11.23 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 632 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 63.61% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.75 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pediatrix Medical Group's Beneish M-Score or its related term are showing as below:

FRA:PDC' s Beneish M-Score Range Over the Past 10 Years
Min: -5.74   Med: -2.54   Max: -1.91
Current: -2.75

During the past 13 years, the highest Beneish M-Score of Pediatrix Medical Group was -1.91. The lowest was -5.74. And the median was -2.54.


Pediatrix Medical Group Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pediatrix Medical Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pediatrix Medical Group Beneish M-Score Chart

Pediatrix Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 -2.37 -2.56 -2.76 -3.00

Pediatrix Medical Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -2.92 -3.05 -3.00 -2.75

FRA:PDC vs SGRY, ADUS, SNDA: Beneish M-Score Comparison

For the Medical Care Facilities subindustry, Pediatrix Medical Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pediatrix Medical Group Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pediatrix Medical Group's Beneish M-Score falls into.


FRA:PDC
63GF Score
Pediatrix Medical Group Inc FRA:PDC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pediatrix Medical Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pediatrix Medical Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0089+0.528 * 0.8972+0.404 * 0.8553+0.892 * 0.9057+0.115 * 1.8187
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0463+4.679 * -0.051041-0.327 * 0.9397
=-2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €205 Mil.
Revenue was 411.91 + 421.68 + 419.929 + 406.488 = €1,660 Mil.
Gross Profit was 97.714 + 107.59 + 119.577 + 108.139 = €433 Mil.
Total Current Assets was €508 Mil.
Total Assets was €1,791 Mil.
Property, Plant and Equipment(Net PPE) was €67 Mil.
Depreciation, Depletion and Amortization(DDA) was €19 Mil.
Selling, General, & Admin. Expense(SGA) was €208 Mil.
Total Current Liabilities was €383 Mil.
Long-Term Debt & Capital Lease Obligation was €368 Mil.
Net Income was 25.58 + 28.765 + 61.095 + 34.038 = €149 Mil.
Non Operating Income was 0.458 + -0.289 + 19.352 + 0.345 = €20 Mil.
Cash Flow from Operations was -112.318 + 97.443 + 116.967 + 118.924 = €221 Mil.
Total Receivables was €224 Mil.
Revenue was 423.982 + 479.758 + 460.553 + 468.491 = €1,833 Mil.
Gross Profit was 94.944 + 122.742 + 105.256 + 106.017 = €429 Mil.
Total Current Assets was €344 Mil.
Total Assets was €1,844 Mil.
Property, Plant and Equipment(Net PPE) was €37 Mil.
Depreciation, Depletion and Amortization(DDA) was €25 Mil.
Selling, General, & Admin. Expense(SGA) was €220 Mil.
Total Current Liabilities was €217 Mil.
Long-Term Debt & Capital Lease Obligation was €606 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(204.995 / 1660.007) / (224.339 / 1832.784)
=0.12349 / 0.122403
=1.0089

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(428.959 / 1832.784) / (433.02 / 1660.007)
=0.234048 / 0.260854
=0.8972

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (507.784 + 67.44) / 1790.805) / (1 - (343.612 + 36.876) / 1843.968)
=0.67879 / 0.793658
=0.8553

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1660.007 / 1832.784
=0.9057

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(25.298 / (25.298 + 36.876)) / (19.437 / (19.437 + 67.44))
=0.40689 / 0.22373
=1.8187

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(208.321 / 1660.007) / (219.818 / 1832.784)
=0.125494 / 0.119937
=1.0463

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((367.979 + 382.882) / 1790.805) / ((606.167 + 216.61) / 1843.968)
=0.419287 / 0.446199
=0.9397

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(149.478 - 19.866 - 221.016) / 1790.805
=-0.051041

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pediatrix Medical Group has a M-score of -2.80 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.75 mean?
Pediatrix Medical Group (FRA:PDC) has a Beneish M-Score of -2.75 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pediatrix Medical Group and its competitors. According to the industry distribution chart, Pediatrix Medical Group ranks #230 out of 632 companies in the Healthcare Providers & Services industry, placing it in the top 36.4%.
Is Pediatrix Medical Group's Beneish M-Score too high?
Pediatrix Medical Group's current Beneish M-Score is -2.75. Based on the distribution chart, Pediatrix Medical Group ranks #230 out of 632 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Beneish M-Score compare to SGRY and ADUS?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #230 out of 632 companies for Beneish M-Score. This puts Pediatrix Medical Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pediatrix Medical Group and its competitors. Pediatrix Medical Group's current Beneish M-Score is -2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.23, compared to a current price of €20.40 — trading 81.7% above its estimated fair value. The current Beneish M-Score is -2.75. Pediatrix Medical Group's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Beneish M-Score is -2.75 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?

Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued. The current stock price of €20.40 is trading 81.7% above its estimated GF Value™ of €11.23. GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.

Key valuation signals for FRA:PDC:

  • Beneish M-Score: -2.75
  • GF Value™: €11.23 vs. price of €20.40 (81.7% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pediatrix Medical Group Business Description

Other Exchanges MD:USA
Address 1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
63GF Score

Get the complete analysis for FRA:PDC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.40
Price
€11.23
GF Value